Role of vasodilator‑stimulated phosphoprotein in RANKL‑differentiated murine macrophage RAW264.7 cells: Modulation of NF‑κB, c‑Fos and NFATc1 transcription factors

Hu,Hao; Li,Chao; Zhang,Haitao; Wu,Gang; Huang,Yong

doi:10.3892/etm.2021.9856

Role of vasodilator‑stimulated phosphoprotein in RANKL‑differentiated murine macrophage RAW264.7 cells: Modulation of NF‑κB, c‑Fos and NFATc1 transcription factors

Authors:
- Hao Hu
- Chao Li
- Haitao Zhang
- Gang Wu
- Yong Huang
View Affiliations

Affiliations: Department of Traditional Chinese Traumatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430061, P.R. China
Published online on: February 25, 2021 https://doi.org/10.3892/etm.2021.9856
Article Number: 412
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vasodilator‑stimulated phosphoprotein (VASP) is essential for osteoclast differentiation, and reduced VASP expression results in depressed osteoclast differentiation. Previously, we demonstrated the importance of VASP and Ras‑related C3 botulinum toxin substrate 1 interactions in osteosarcoma cell migration and metastasis using Mg‑63 and Saos2 cells. However, the molecular details of the functional role of VASP in cell motility and migration remain to be elucidated. The present study demonstrated that VASP affects the expression of αV‑integrin, tartrate‑resistant acid phosphatase (TRAP) and lamellipodia protrusion in RAW 264.7 murine macrophage cells. The RAW 264.7 mouse monocyte macrophage cell line was used as an osteoclast precursor. RAW 264.7 cells were treated with 50 ng/ml of receptor activator of nuclear factor κ‑Β ligand (RANKL) in order to induce cell differentiation (osteoclastogenesis). Small interfering RNA (siRNA) was used to silence VASP, and RT‑PCR and western blotting were used to determine the expression for genes and proteins, respectively. TRAP staining as a histochemical marker for osteoclast and fluorescent microscopy for lamellipodia protrusion was performed. RANKL treatment significantly increased the gene and protein expression of VASP, αV‑integrin and TRAP in RAW 264.7 cells. Silencing of VASP significantly reduced the RANKL‑induced expression of αV‑integrin, TRAP and lamellipodia protrusion. In addition, knockdown of VASP attenuated RANKL‑stimulated activation of NF‑κB, c‑Fos and nuclear factor of activated T cells cytoplasmic 1 transcription factors, and the phosphorylation of the p65 and IκBα. These results suggest the critical role of VASP in regulating osteoclast differentiation, which should be further explored in osteosarcoma research.

View Figures

View References

1	Rachubik P and Piwkowska A: The role of vasodilator-stimulated phosphoprotein in podocyte functioning. Cell Biol Int. 43:1092–1101. 2019.PubMed/NCBI View Article : Google Scholar
2	Wu G, Wei L, Yu A, Zhang M, Qi B, Su K, Hu X and Wang J: Vasodilator-stimulated phosphoprotein regulates osteosarcoma cell migration. Oncol Rep. 26:1609–1615. 2011.PubMed/NCBI View Article : Google Scholar
3	Li K, Ma YB, Tian YH, Xu XL, Gao Y, He YQ, Pan WT, Zhang JW, He CJ and Wei L: Silencing lncRNA SNHG6 suppresses proliferation and invasion of breast cancer cells through miR-26a/VASP axis. Pathol Res Pract. 215(152575)2019.PubMed/NCBI View Article : Google Scholar
4	Aszódi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, Andersson KE, Kehrel B, Offermanns S and Fässler R: The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 18:37–48. 1999.PubMed/NCBI View Article : Google Scholar
5	Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, et al: Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol. 103:5–10. 2009.PubMed/NCBI View Article : Google Scholar
6	Park JH, Lee NK and Lee SY: Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells. 40:706–713. 2017.PubMed/NCBI View Article : Google Scholar
7	van Dam PA, Verhoeven Y, Trinh XB, Wouters A, Lardon F, Prenen H, Smits E, Baldewijns M and Lammens M: RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 133:85–91. 2019.PubMed/NCBI View Article : Google Scholar
8	Cheng AM, Rizzo-DeLeon N, Wilson CL, Lee WJ, Tateya S, Clowes AW, Schwartz MW and Kim F: Vasodilator-stimulated phosphoprotein protects against vascular inflammation and insulin resistance. Am J Physiol Endocrinol Metab. 307:E571–E579. 2014.PubMed/NCBI View Article : Google Scholar
9	Zeng XZ, He LG, Wang S, Wang K, Zhang YY, Tao L, Li XJ and Liu SW: Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression. Acta Pharmacol Sin. 37:255–263. 2016.PubMed/NCBI View Article : Google Scholar
10	Brito C, Stavroullakis AT, Ferreira AC, Li K, Oliveira T, Nogueira-Filho G and Prakki A: Extract of acai-berry inhibits osteoclast differentiation and activity. Arch Oral Biol. 68:29–34. 2016.PubMed/NCBI View Article : Google Scholar
11	Lee SH, Kim JK and Jang HD: Genistein inhibits osteoclastic differentiation of RAW 264.7 cells via regulation of ROS production and scavenging. Int J Mol Sci. 15:10605–10621. 2014.PubMed/NCBI View Article : Google Scholar
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
13	Oliveira V, Mahajan N, Bates ML, Tripathi C, Kim KQ, Zaher HS, Maggi LB Jr and Tomasson MH: The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis. FASEB Bioadv. 1:404–414. 2019.PubMed/NCBI View Article : Google Scholar
14	Gang W, Tanjun W, Yong H, Jiajun Q, Yi Z and Hao H: Inhibition of miR-9 decreases osteosarcoma cell proliferation. Bosn J Basic Med Sci. 20:218–225. 2020.PubMed/NCBI View Article : Google Scholar
15	Mahajan N, Hoover B, Rajendram M, Shi HY, Kawasaki K, Weibel DB and Zhang M: Maspin binds to cardiolipin in mitochondria and triggers apoptosis. FASEB J. 33:6354–6364. 2019.PubMed/NCBI View Article : Google Scholar
16	Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y and Kim HH: Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun. 351:99–105. 2006.PubMed/NCBI View Article : Google Scholar
17	Chen Y, Di Grappa MA, Molyneux SD, McKee TD, Waterhouse P, Penninger JM and Khokha R: RANKL blockade prevents and treats aggressive osteosarcomas. Sci Transl Med. 7(317ra197)2015.PubMed/NCBI View Article : Google Scholar
18	Zhao H, Gu J, Dai N, Gao Q, Wang D, Song R, Liu W, Yuan Y, Bian J, Liu X and Liu Z: Osteoprotegerin exposure at different stages of osteoclastogenesis differentially affects osteoclast formation and function. Cytotechnology. 68:1325–1335. 2016.PubMed/NCBI View Article : Google Scholar
19	Applewhite DA, Barzik M, Kojima SI, Svitkina TM, Gertler FB and Borisy GG: Ena/VASP proteins have an anti-capping independent function in filopodia formation. Mol Biol Cell. 18:2579–2591. 2007.PubMed/NCBI View Article : Google Scholar
20	Bear JE and Gertler FB: Ena/VASP: Towards resolving a pointed controversy at the barbed end. J Cell Sci. 122:1947–1953. 2009.PubMed/NCBI View Article : Google Scholar
21	Yu J, Yun H, Shin B, Kim Y, Park ES, Choi S, Yu J, Amarasekara DS, Kim S, Inoue JI, et al: Interaction of tumor necrosis factor receptor-associated factor 6 (TRAF6) and Vav3 in the receptor activator of nuclear factor κB (RANK) signaling complex enhances osteoclastogenesis. J Biol Chem. 291:20643–20660. 2016.PubMed/NCBI View Article : Google Scholar
22	Amarasekara DS, Yun H, Kim S, Lee N, Kim H and Rho J: Regulation of osteoclast differentiation by cytokine networks. Immune Netw. 18(e8)2018.PubMed/NCBI View Article : Google Scholar
23	Feng X and Teitelbaum SL: Osteoclasts: New insights. Bone Res. 1:11–26. 2013.PubMed/NCBI View Article : Google Scholar
24	Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D and Rédini F: Regulation of osteoclast protease expression by RANKL. Biochem Biophys Res Commun. 310:774–778. 2003.PubMed/NCBI View Article : Google Scholar
25	Honig A, Rieger L, Kapp M, Krockenberger M, Eck M, Dietl J and Kämmerer U: Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: An investigational study. BMC Cancer. 6(199)2006.PubMed/NCBI View Article : Google Scholar
26	Liu Z, Wang Y, Dou C, Xu M, Sun L, Wang L, Yao B, Li Q, Yang W, Tu K and Liu Q: Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma. Theranostics. 8:4649–4663. 2018.PubMed/NCBI View Article : Google Scholar
27	Schmidt S, Nakchbandi I, Ruppert R, Kawelke N, Hess MW, Pfaller K, Jurdic P, Fässler R and Moser M: Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption. J Cell Biol. 192:883–897. 2011.PubMed/NCBI View Article : Google Scholar
28	Linder S and Kopp P: Podosomes at a glance. J Cell Sci. 118:2079–2082. 2005.PubMed/NCBI View Article : Google Scholar
29	Helfrich MH, Nesbitt SA, Lakkakorpi PT, Barnes MJ, Bodary SC, Shankar G, Mason WT, Mendrick DL, Väänänen HK and Horton MA: Beta 1 integrins and osteoclast function: Involvement in collagen recognition and bone resorption. Bone. 19:317–328. 1996.PubMed/NCBI View Article : Google Scholar
30	Feng MX, Hong JX, Wang Q, Fan YY, Yuan CT, Lei XH, Zhu M, Qin A, Chen HX and Hong D: Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts. Sci Rep. 6(19074)2016.PubMed/NCBI View Article : Google Scholar
31	Chen Z, Andreev D, Oeser K, Krljanac B, Hueber A, Kleyer A, Voehringer D, Schett G and Bozec A: Th2 and eosinophil responses suppress inflammatory arthritis. Nat Commun. 7(11596)2016.PubMed/NCBI View Article : Google Scholar
32	Tian Y, Xu L, He Y, Xu X, Li K, Ma Y, Gao Y, Wei D and Wei L: Knockdown of RAC1 and VASP gene expression inhibits breast cancer cell migration. Oncol Lett. 16:2151–2160. 2018.PubMed/NCBI View Article : Google Scholar
33	Liu K, Li L, Nisson PE, Gruber C, Jessee J and Cohen SN: Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein. Mol Cell Biol. 19:3696–3703. 1999.PubMed/NCBI View Article : Google Scholar
34	Abu-Amer Y: NF-κB signaling and bone resorption. Osteoporos Int. 24:2377–2386. 2013.PubMed/NCBI View Article : Google Scholar
35	Mussbacher M, Salzmann M, Brostjan C, Hoesel B, Schoergenhofer C, Datler H, Hohensinner P, Basílio J, Petzelbauer P, Assinger A and Schmid JA: Cell type-specific roles of NF-κB linking inflammation and thrombosis. Front Immunol. 10(85)2019.PubMed/NCBI View Article : Google Scholar
36	Wada T, Nakashima T, Hiroshi N and Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 12:17–25. 2006.PubMed/NCBI View Article : Google Scholar